Navigation Links
Anthera Announces Positive Phase II Clinical Results From A-002 Cardiovascular Disease Trial
Date:10/24/2007

SAN MATEO, Calif., Oct. 24 /PRNewswire/ -- Anthera Pharmaceuticals, Inc., a privately-held biopharmaceutical company, reported results of a Phase II clinical trial of its first compound, A-002, for the treatment of cardiovascular disease. The trial results suggest that treatment with A-002 resulted in significant reductions in blood levels of total cholesterol, Non- High Density Lipoprotein Cholesterol (non HDL-C), and Low Density Lipoprotein Cholesterol (LDL-C), known as "bad" cholesterol, coupled with equally meaningful reductions of C-Reactive Protein (CRP), a recognized marker of inflammation and cardiovascular risk. Decreases in these levels with A-002 treatment were most significant among patients already on a background of statin therapy.

The Phase II PLASMA trial (Phospholipase Levels And Serological Markers of Atherosclerosis) was a multi-center, randomized, double-blind, placebo- controlled trial that enrolled approximately 400 patients with stable coronary heart disease in the U.S. and Ukraine. Subjects were randomized to receive one of four different doses of A-002 or placebo for up to eight weeks. Patients also received doctor-determined standard of care therapies. The primary endpoint, a reduction in secretory phospholipase A2 (sPLA2) levels was achieved with a high degree of statistical significance. In addition, the results also demonstrated clinically meaningful as well as statistically significant decreases in cholesterol levels (LDL-C, non-HDL and total cholesterol) in patients with stable coronary heart disease. Clinically meaningful decreases in inflammation, as measured by levels of CRP, were also observed in the relevant patient population. Full data will be presented in a scientific journal during 2008.

"The results of the PLASMA trial support our belief that A-002's unique mechanism of action has a dual effect on lipids and inflammation, which could provide significant therapeutic benefit to patients currently on backgroun
'/>"/>

SOURCE Anthera Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Corporation (NASDAQ: TECH ) announced today that ... new Simple Plex platform through its Proteins Platform division ... of the previously acquired CyPlex instrument platform from CyVek. ... immunoassay technology which integrates an innovatively designed microfluidic cartridge ...
(Date:1/22/2015)... , Jan. 22, 2015 Research and Markets ... "Infectious Disease Diagnostics Market by Product, Application, Technology, ... to their offering. , The infectious disease ... 7.9% to reach $18,156.2 million by 2019 from $12,422.8 ...
(Date:1/22/2015)... BETHESDA, Md. , Jan. 22, 2015 The Parenteral ... Manufacturing Science Program SM : Enabling Pharmaceutical Manufacturing,s Future. ... will fulfill the following goals: , Highlight the ... , Strengthen and build practical solutions by filling known gaps ...
Breaking Medicine Technology:Bio-Techne Launches Simple Plex Platform 2Bio-Techne Launches Simple Plex Platform 3Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 2Global Infectious Disease Diagnostics (Instruments, Reagents, Services, Software) Market - Forecast to 2019 3PDA Launches Manufacturing Science Program(SM) 2PDA Launches Manufacturing Science Program(SM) 3
... Ameritox (SM), the nation,s leader in Pain Medication Monitoring ... Record for the Congressional hearing on "Costs of Prescription ... to medication monitoring as a potential solution to improving ... in lowering national healthcare costs. The hearing was held ...
... /PRNewswire-Asia/ -- China Kanghui Holdings (NYSE: KH ... manufacturer and marketer of orthopedic implants in China, today ... 2011 financial results on November 9, 2011, after the ... conference call and live webcast at 8:00 a.m. ET ...
Cached Medicine Technology:Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients 2Ameritox Supports Federal Implementation of Medication Monitoring for Chronic Pain Patients 3China Kanghui Holdings to Report Third Quarter 2011 Financial Results 2
(Date:1/22/2015)... The City of West Hollywood hosted a news conference ... 42nd anniversary of the Supreme Court decision Roe v. Wade, which ... since the Roe vs. Wade decision and the fight to protect ... said City of West Hollywood Councilmember Abbe Land. “We need to ...
(Date:1/22/2015)... The Incredible Bulk is a revolutionary method ... lean muscle by up to 30lbs in less than 12 ... HealthyandFitZone.com’s Stan Stevenson, prompting an investigative review. , “Our ... scientific diet formula that allows the body to pack on ...
(Date:1/22/2015)... January 22, 2015 Juvent Sports ( ... the 2015 PGA Merchandise Show to bestow a Juvent ... female amateur golfer, Arlene McKitrick. The award commemorated and ... golf tournament win. She won her first amateur tournament ...
(Date:1/22/2015)... 22, 2015 Carinsurancesavings.biz has released a new ... and dismemberment insurance . , Purchasing an accidental death ... very advantageous. This type of rider provides benefits if the ... be considered a lesser form of life insurance. , ...
(Date:1/22/2015)... IsoComforter, Inc. has introduced the most innovative and ... to treat specific body parts and muscle groups. , ... to use patented cold therapy machine with the innovative IsoTube ... muscle injuries. IsoComforter has become the industry leader in ...
Breaking Medicine News(10 mins):Health News:The Incredible Bulk: Review Examining Ben Pakulski’s Brand New Bulking Muscle Building Diet Program Released 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 2Health News:All-Time Leading Female Amateur Golfer Arlene McKitrick Receives Juvent Sports Achievement Award at 2015 PGA Show 3Health News:Accidental Death and Dismemberment Insurance Can Be Purchased at Low Prices Online 2Health News:IsoComforter Introduces Best of Class Cold Therapy Product to the Worldwide Market 2
... September 27th, 2011 InterCure Ltd., a medical device ... INCR), today announced that European Journal of Heart ... European Society of Cardiology, published the results of a ... modulation with RESPeRATE applied at the home setting can ...
... early diagnostic test for Alzheimer,s disease (AD), scientists have discovered ... levels of a protein linked to pregnancy years before showing ... Research. Theo Luider and colleagues explain that more ... numbers are rising with the graying of the population. Doctors ...
... at Johns Hopkins have modified HIV in a way that ... Their work, they say in a report published online September ... major hurdle in HIV vaccine development and lead to new ... immune response, rather than triggering it, making it a tough ...
... , WEDNESDAY, Sept. 28 (HealthDay News) -- Just ... weeks, gestation can have impaired lung function at ages 8 ... may improve by the time they are teenagers, research shows. ... negative effects that extreme premature birth can have on the ...
... end of life does not cause them any harm, contrary ... Journal of Hospital Medicine found that patients who ... advance directive in their medical record have similar survival rates ... The study included 356 patients admitted at three different ...
... women consider themselves to be the more robust side of ... new research, published in BioEssays, seems to support the idea. ... the X chromosome to explain why women have stronger immune ... The research, led by Dr Claude Libert from Ghent ...
Cached Medicine News:Health News:European Journal of Heart Failure publishes new randomized controlled clinical study of RESPeRATE 2Health News:Hide-and-seek: Altered HIV can't evade immune system 2Health News:Lung Function of Late Preemies May Improve With Age 2Health News:Women have stronger immune systems than men and it's all down to a single chromosome 2
... has the highest g-force ever. But optimal ... force. Optima MAX combines maximum force, capacity, ... performance that's worlds apart from any other ... and enhanced efficiency, Optima takes productivity to ...
... versatility, and environmental safety are ... LE-80 K Ultracentrifuge from Beckman ... Optima centrifugation technology, the LE-80 ... effectively provide advanced capability for ...
... Capable of generating 694,000 ... to 90,000 rpm, Beckman Coulter's ... to perform more separations in ... model operates with a broad ...
... L-XP ultracentrifuge is designed to play ... process if research involves proteomics, cytomics ... on-board computer, enhanced firmware, powerful Optima ... screen, Optima L-XP delivers superior functionality, ...
Medicine Products: